Navigation Links
Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
Date:9/19/2007

ave been issued and are pending on these proprietary technologies.

Under the terms of the agreement, Adams receives an exclusive, royalty- bearing license from Lipocine to develop and market multiple prescription adult cough products in North America. Lipocine is responsible for completing the product development work and will be eligible to receive reimbursements and payments in exchange for completing certain pre-defined development milestones. Adams will be responsible for performing all aspects of clinical development, regulatory submission, manufacture and commercial operations. Financial terms of the deal are not being disclosed. Adams reconfirms that it expects diluted earnings per share in fiscal 2008 to be in the range of $1.55 to $1.75, as previously disclosed in an August 21, 2007 press release.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

About Lipocine Inc.

Lipocine Inc. is a pharmaceutical company leveraging its proprietary drug delivery technologies to commercialize innovative pharmaceutical products. Lipocine business objectives are to develop products with established drugs that have patient friendly attributes such as faster absorption, lower dose, fewer side effects, less frequent dosing, and no food effect.

Adams Respiratory Therapeutics Forward-Looking Statement

This press release contains certain "forward-looking" statements, including Adams' application of the Lip'ral(TM) technology to prescription cough products, Adams' competitiveness in the prescription cough and cold market and Adams' future financial performance. Such forward-looking statements can be identified by the words "could," "will" and similar expressions and are subject to risks and uncertainties that could cause actual results to
'/>"/>

SOURCE Adams Respiratory Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. NanoRite Innovation Center opens with small science, big promise
3. UW-Madison to receive $125M for bioenergy research center
4. WARF enters licensing agreements for stem cell products
5. Internet-enabled niche markets take center stage
6. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
7. TomoTherapy opens technical training center
8. Stem cell and regenerative medicine center to aid education and commerce
9. Mega-Metro Center may go beyond Chicago and Wisconsin
10. Software company enters health space with RFID solutions on hold
11. Former Fiserv exec to enter Business Hall of Fame
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... DIEGO , April 23, 2015  Neurocrine Biosciences, ... Company will report its first quarter 2015 results before ... Neurocrine will then host a live conference call and webcast ... update Thursday morning, April 30, 2015 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1906 ...
(Date:4/23/2015)... , April 23, 2015  Veracyte, Inc. (NASDAQ: VCYT ... definitive agreement to sell approximately $40 million of its ... the investors will purchase an aggregate of 4,907,975 shares ... per share, the closing stock price on April 22, ... existing investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood ...
(Date:4/23/2015)... -- Metanome, Inc., an industry leader in comprehensive microbiome ... name to Diversigen, Inc.  The name was changed ... source for the myriad of services and expertise ... of the microbiome.  From the wide diversity in ... that are difficult to handle, such as low ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2
... BUENOS AIRES, Argentina, March 30 The Development Group ... met in the city of Buenos Aires in order ... Criteria." , (Logo: ... document will be formally submitted at the 4th International,Conference ...
... CRANBURY, N.J., March 30 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming 16th ... Biotech Industry conference at New York City,s Millennium Broadway ... to begin on Thursday, April 2, 2009 at 9:30 a.m. ...
... March 30 InterMune, Inc. (Nasdaq: ITMN ) ... and President of InterMune, will present at Citi,s 4th Annual ... at 10:40 a.m. EDT. To access a live audio ... log on to the investor relations page of InterMune,s corporate ...
Cached Biology Technology:International Soy Experts Meeting in Argentina Called by the Round Table on Responsible Soy Association (RTRS) 2
(Date:3/31/2015)... YORK , March 31, 2015  Elephant Talk ... "Company"), a global provider of Software Defined Network Architecture ... today announced total revenue of approximately $20.4 million for ... a restated $19.5 million for the year ended December ... calendar 2014, the Company had completed its multi-year transition ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... are important vehicles for the transmission of enteric ... including human pathogens, are particularly abundant in bivalve ... procedures, thus representing a potential risk for human ... to affect the persistence of vibrios in these ...
... population of North Pacific right whales, found during the summer ... whale populations in the world. Commercial whaling in the 1800s ... these whales have been recognized as a different species from ... the Southern Hemisphere. , To help define areas and ecological ...
... in northern China starting as far back as 2400 ... farming combined with other crops, says University of Toronto ... with Chinese agriculture, most archeologists have, until recently, thought ... food associated with northern China. However, recent archeological research ...
Cached Biology News:Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
... CELSR3 is an Orphan-U GPCR with ... is expressed during development at sites of active ... brain, spinal cord, dorsal root ganglion, and eye. ... brain, colon, heart/melanocyte/uterus, lung, nerve, and placenta libraries. ...
Biology Products: